Drug Profile
Anti-MG7 chimeric antigen receptor T cell therapy - Shanghai Genechem
Alternative Names: Anti-MG7 CAR-T cell-therapy; Anti-MG7 CAR-T cells; MG7 CAR-T-cells; MG7 chimeric antigen receptor T cells; MG7-targeted chimeric antigen receptor T cellsLatest Information Update: 18 Feb 2022
Price :
$50
*
At a glance
- Originator Shanghai Genechem
- Developer Shanghai Genechem; Xijing Hospital
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Liver metastases
Most Recent Events
- 18 Feb 2022 Discontinued - Phase-I/II for Liver metastases in China (Intratumoural)
- 01 Jun 2016 Phase-I/II clinical trials in Liver metastases (In adults) in China (Intratumoural) (NCT02862704)